Standard

Reaction time in healthy elderly is associated with chronic low-grade inflammation and advanced glycation end product. / Arnold, Pauline; Njemini, Rose; Vantieghem, Stijn; Gorus, Ellen; Pool-Goudzwaard, Annelies; Buyl, Ronald; Bautmans, Ivan.

In: Experimental Gerontology, Vol. 108, 15.07.2018, p. 118-124.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

BibTeX

@article{9540996d0b334bb3a91281e9cf09c386,
title = "Reaction time in healthy elderly is associated with chronic low-grade inflammation and advanced glycation end product",
abstract = "Chronic inflammation and Advanced Glycation End products (AGE) are associated with sarcopenia. Decreased voluntary muscle activation and increased antagonist coactivation can contribute to age-related muscle weakness. The influence of chronic inflammation and AGE in these neuromuscular mechanisms is not clear. We studied whether a relation exists between circulating levels of inflammatory cytokines and AGEs as well as the interplay between agonist and antagonist muscle activation. We studied 64 community-dwelling old subjects, during a maximal isometric voluntary contraction (MVC) and a reaction-time (RT) test of the upper limb. Twenty-five circulating inflammatory biomarkers were determined. Linear regression showed significant relationships between chronic inflammation and six muscle activation parameters. MIP-1β showed a significant negative relation with antagonist coactivation (during MVC) and antagonist muscle activity during pre-movement time (PMT) and movement time (MT) (during RT). A higher level of pentosidine (AGE) was predictive for a longer PMT. We conclude that in older relatively healthy persons antagonist muscle activation is influenced by chronic inflammation, contributing to age-related muscle weakness. Our results also suggest a mechanical and inflammatory influence of pentosidine in upper limb slowing of movement. These findings show novel insight in underlying mechanisms of age-related muscle weakness.",
keywords = "Advanced glycation end product, Aging, Antagonist coactivation, Chronic inflammation, Cytokines",
author = "Pauline Arnold and Rose Njemini and Stijn Vantieghem and Ellen Gorus and Annelies Pool-Goudzwaard and Ronald Buyl and Ivan Bautmans",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = "7",
day = "15",
doi = "10.1016/j.exger.2018.04.002",
language = "English",
volume = "108",
pages = "118--124",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Reaction time in healthy elderly is associated with chronic low-grade inflammation and advanced glycation end product

AU - Arnold, Pauline

AU - Njemini, Rose

AU - Vantieghem, Stijn

AU - Gorus, Ellen

AU - Pool-Goudzwaard, Annelies

AU - Buyl, Ronald

AU - Bautmans, Ivan

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Chronic inflammation and Advanced Glycation End products (AGE) are associated with sarcopenia. Decreased voluntary muscle activation and increased antagonist coactivation can contribute to age-related muscle weakness. The influence of chronic inflammation and AGE in these neuromuscular mechanisms is not clear. We studied whether a relation exists between circulating levels of inflammatory cytokines and AGEs as well as the interplay between agonist and antagonist muscle activation. We studied 64 community-dwelling old subjects, during a maximal isometric voluntary contraction (MVC) and a reaction-time (RT) test of the upper limb. Twenty-five circulating inflammatory biomarkers were determined. Linear regression showed significant relationships between chronic inflammation and six muscle activation parameters. MIP-1β showed a significant negative relation with antagonist coactivation (during MVC) and antagonist muscle activity during pre-movement time (PMT) and movement time (MT) (during RT). A higher level of pentosidine (AGE) was predictive for a longer PMT. We conclude that in older relatively healthy persons antagonist muscle activation is influenced by chronic inflammation, contributing to age-related muscle weakness. Our results also suggest a mechanical and inflammatory influence of pentosidine in upper limb slowing of movement. These findings show novel insight in underlying mechanisms of age-related muscle weakness.

AB - Chronic inflammation and Advanced Glycation End products (AGE) are associated with sarcopenia. Decreased voluntary muscle activation and increased antagonist coactivation can contribute to age-related muscle weakness. The influence of chronic inflammation and AGE in these neuromuscular mechanisms is not clear. We studied whether a relation exists between circulating levels of inflammatory cytokines and AGEs as well as the interplay between agonist and antagonist muscle activation. We studied 64 community-dwelling old subjects, during a maximal isometric voluntary contraction (MVC) and a reaction-time (RT) test of the upper limb. Twenty-five circulating inflammatory biomarkers were determined. Linear regression showed significant relationships between chronic inflammation and six muscle activation parameters. MIP-1β showed a significant negative relation with antagonist coactivation (during MVC) and antagonist muscle activity during pre-movement time (PMT) and movement time (MT) (during RT). A higher level of pentosidine (AGE) was predictive for a longer PMT. We conclude that in older relatively healthy persons antagonist muscle activation is influenced by chronic inflammation, contributing to age-related muscle weakness. Our results also suggest a mechanical and inflammatory influence of pentosidine in upper limb slowing of movement. These findings show novel insight in underlying mechanisms of age-related muscle weakness.

KW - Advanced glycation end product

KW - Aging

KW - Antagonist coactivation

KW - Chronic inflammation

KW - Cytokines

UR - http://www.scopus.com/inward/record.url?scp=85045556730&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2018.04.002

DO - 10.1016/j.exger.2018.04.002

M3 - Article

C2 - 29630924

VL - 108

SP - 118

EP - 124

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -

ID: 37401749